US formulations revenue rose 2.2 per cent year on year to ₹3,739 crore, while European revenue increased 27.4 per cent to ₹2,703 crore.
| Photo Credit:
iStockphoto
Aurobindo Pharma Ltd has posted a net profit of ₹910 crore for the quarter ended December 31, 2025, as against ₹846 crore in the same quarter last year, showing a growth of 7.6 per cent.
The company’s revenue stood at ₹8,646 crore (₹7,979 crore) in the quarter – up 8.4 per cent.
“The quarter reflected steady execution across our core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the US and Europe,” K Nithyananda Reddy, Vice-Chairman and Managing Director of the company, said in a press release.
“Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability. As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation over the medium term,” he said.
US formulations revenue rose 2.2 per cent year on year to ₹3,739 crore, while European revenue increased 27.4 per cent to ₹2,703 crore. The aggregate formulation revenue stood at ₹7,683 crore (₹6,960 crore), reflecting a 10.4 per cent growth.
The company’s board of directors approved the proposal to acquire a 26 per cent stake in Garuda Renewables Private Ltd for ₹66 crore and to enter into a power purchase agreement with the target company to procure renewable energy from hybrid wind-solar sources.
Published on February 9, 2026